Search research articles
Contact Us
Filters
Showing results (91-100 of 96) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 96 results.
Blood
|
March 29, 2024
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma
Annamaria Gulla, Eugenio Morelli, Megan Johnstone, et al.
Leukemia
|
January 14, 2022
Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma
Johannes M Waldschmidt, Andrew J Yee, Tushara Vijaykumar, et al.
American Journal of Hematology
|
February 8, 2022
Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma
Peter O'Gorman, Jacob P Laubach, Michael E O'Dwyer, et al.
Blood
|
June 2, 2021
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity
Antonio Sacco, Cinzia Federico, Katia Todoerti, et al.
Haematologica
|
May 28, 2026
A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma
Omar Nadeem, Robert A Redd, Peter M Barth, et al.
Blood
|
September 20, 2022
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth
Eugenio Morelli, Mariateresa Fulciniti, Mehmet K Samur, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 96) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 96 results.
Blood
|
March 29, 2024
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma
Annamaria Gulla, Eugenio Morelli, Megan Johnstone, et al.
Leukemia
|
January 14, 2022
Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma
Johannes M Waldschmidt, Andrew J Yee, Tushara Vijaykumar, et al.
American Journal of Hematology
|
February 8, 2022
Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma
Peter O'Gorman, Jacob P Laubach, Michael E O'Dwyer, et al.
Blood
|
June 2, 2021
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity
Antonio Sacco, Cinzia Federico, Katia Todoerti, et al.
Haematologica
|
May 28, 2026
A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma
Omar Nadeem, Robert A Redd, Peter M Barth, et al.
Blood
|
September 20, 2022
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth
Eugenio Morelli, Mariateresa Fulciniti, Mehmet K Samur, et al.
Page
of 10